Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================

CHAMPIONS TACKLING MS - AWARDS Dinner, Honoring Aaron Boster, MD and Jon e. Glaser, DDS - now open for registration. Visit www.events.msvn.org

Monday, November 14, 2016

Development of an MS medication (MT1303) that showed promising results, has been discontinued


                                                                  
  

Click here to receive MS news via e-mail



Amiselimod (former MT-1303) is an investigational sphingosine 1-phosphate (S1P) receptor modulator that was in development by Biogen for people with relapsing-remitting multiple sclerosis RRMS, inflammatory bowel disease, and other autoimmune conditions.
S1P receptor modulators interfere with S1P signaling. They block lymphocytes (immune cells) from receiving exit signals inside the lymph nodes, which keeps the immune cells trapped inside the node. The result is a reduction of circulating T- and B-cells leading to anti-inflammatory activity because it stops the migration of certain immune cells to the actual sites of inflammation.
A Phase 2 study (NCT01742052) of amiselimod in patients with RRMS was completed in September with successful and promising results. Amiselimod (0.2 mg and 0.4 mg) significantly reduced the total number of brain lesions and produced a safety and effectiveness profile that suggested it should be furthered studied as  a new potential treatment for people with RRMS.
Although the trial results showed positive results, Biogen has discontinued development of amiselimod without explanation, according to a press release.
Read complete story here




MS Views and News
Providing educational information, resources and services for those affected by MS

No comments: